Mizuho Securities analyst Irina Rivkind Koffler reiterated a Hold rating on Mylan Inc (MYL) today. The company’s shares closed yesterday at $20.08, close to its 52-week low of $19.73.
Rivkind Koffler noted:
“We lower our PT to $26 from $32 due to a higher 11% WACC in the DCF related to execution risk and pricing collusion headline risk. We also believe that the Mylan business transformation may take several years to play out.”
According to TipRanks.com, Koffler is a 2-star analyst with an average return of 0.2% and a 38.5% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Assertio Therapeutics Inc.
Mylan Inc has an analyst consensus of Moderate Buy, with a price target consensus of $31, representing a 54.4% upside. In a report issued on May 7, Wells Fargo also downgraded the stock to Hold with a $22 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $42.50 and a one-year low of $19.73. Currently, Mylan Inc has an average volume of 6.93M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World.
